NO20006148L - Stabilisering av preparater inneholdende ACE inhibitorer ved anvendelse av magnesiumoksyd - Google Patents

Stabilisering av preparater inneholdende ACE inhibitorer ved anvendelse av magnesiumoksyd

Info

Publication number
NO20006148L
NO20006148L NO20006148A NO20006148A NO20006148L NO 20006148 L NO20006148 L NO 20006148L NO 20006148 A NO20006148 A NO 20006148A NO 20006148 A NO20006148 A NO 20006148A NO 20006148 L NO20006148 L NO 20006148L
Authority
NO
Norway
Prior art keywords
stabilization
magnesium oxide
preparations containing
ace inhibitors
containing ace
Prior art date
Application number
NO20006148A
Other languages
English (en)
Norwegian (no)
Other versions
NO20006148D0 (no
Inventor
Jane Ellen Daniel
Michael Ray Harris
Gerard Clifford Hokanson
Jay Weiss
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22210458&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20006148(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO20006148L publication Critical patent/NO20006148L/no
Publication of NO20006148D0 publication Critical patent/NO20006148D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20006148A 1998-06-05 2000-12-04 Stabilisering av preparater inneholdende ACE inhibitorer ved anvendelse av magnesiumoksyd NO20006148D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8828098P 1998-06-05 1998-06-05
PCT/US1999/010189 WO1999062560A1 (en) 1998-06-05 1999-05-10 Stabilization of compositions containing ace inhibitors using magnesium oxide

Publications (2)

Publication Number Publication Date
NO20006148L true NO20006148L (no) 2000-12-04
NO20006148D0 NO20006148D0 (no) 2000-12-04

Family

ID=22210458

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20006148A NO20006148D0 (no) 1998-06-05 2000-12-04 Stabilisering av preparater inneholdende ACE inhibitorer ved anvendelse av magnesiumoksyd

Country Status (32)

Country Link
US (3) US6417196B1 (pt)
EP (1) EP1083931B1 (pt)
JP (1) JP3727848B2 (pt)
KR (1) KR20010052557A (pt)
CN (1) CN1144598C (pt)
AR (1) AR019150A1 (pt)
AT (1) ATE295184T1 (pt)
AU (1) AU755616B2 (pt)
BR (1) BR9910947A (pt)
CA (1) CA2330581A1 (pt)
CO (1) CO5011043A1 (pt)
DE (1) DE69925269T2 (pt)
ES (1) ES2242398T3 (pt)
GT (1) GT199900079A (pt)
HK (1) HK1038879B (pt)
HN (1) HN1999000088A (pt)
HU (1) HUP0102260A3 (pt)
ID (1) ID27398A (pt)
IL (1) IL139590A0 (pt)
IS (1) IS2270B (pt)
MY (1) MY119667A (pt)
NO (1) NO20006148D0 (pt)
NZ (1) NZ508544A (pt)
PA (1) PA8475001A1 (pt)
PE (1) PE20000543A1 (pt)
PL (1) PL344586A1 (pt)
SV (1) SV1999000072A (pt)
TR (1) TR200003600T2 (pt)
TW (1) TW565455B (pt)
UY (1) UY25546A1 (pt)
WO (1) WO1999062560A1 (pt)
ZA (1) ZA200006537B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999062560A1 (en) * 1998-06-05 1999-12-09 Warner-Lambert Company Stabilization of compositions containing ace inhibitors using magnesium oxide
NZ333206A (en) * 1998-12-08 2000-07-28 Bernard Charles Sherman Solid pharmaceutical compositions comprising a stable magnesium salt of quinapril that acts as a ACE (Angiotensin Converting Enzyme) inhibitor
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
KR100741937B1 (ko) * 2000-05-24 2007-07-24 오츠카 세이야쿠 가부시키가이샤 제제의 안정화 방법
ES2283774T3 (es) * 2002-01-15 2007-11-01 Actavis Group Hf. Formulaciones de quinapril e inhibidores de la eca relacionados.
US20030157165A1 (en) * 2002-02-01 2003-08-21 Sherman Bernard Charles Stable saccharide-free tablets comprising a salt of quinapril or moexipril
US7638138B2 (en) 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
AU2003220808B2 (en) 2003-03-27 2008-08-21 Bioactis Limited Powder medicine applicator for nasal cavity
CZ298224B6 (cs) * 2003-04-29 2007-07-25 Pliva Istrazivanje I Razvoj D.O.O. Farmaceutická kompozice obsahující jako úcinnou látku ribavirin a zpusob její výroby
MXPA06000226A (es) * 2003-06-26 2006-03-21 Teva Pharma Composiciones farmaceuticas estables de derivados del acido 2-aza-biciclo[3.3..0]-octano-3-carboxilico.
WO2006016530A1 (ja) * 2004-08-10 2006-02-16 Translational Research, Ltd. 速効性でかつ高い吸収性を可能とする経鼻投与用組成物
US20060141054A1 (en) * 2004-10-25 2006-06-29 Thomas Piccariello Metal coordinated compositions
US8779175B2 (en) 2004-10-25 2014-07-15 Synthonics, Inc. Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients
US7799937B2 (en) 2004-10-25 2010-09-21 Synthonics, Inc. Metal coordinated compositions
ITMI20060026A1 (it) * 2006-01-10 2007-07-11 Truffini & Regge Farmaceutici Srl Composizioni per uso rale a base di s-adenosilmetionina e processo per il loro ottenimento
EP1815857A1 (en) 2006-02-02 2007-08-08 LEK Pharmaceuticals D.D. A pharmaceutical composition comprising perindopril
US20070232680A1 (en) * 2006-04-04 2007-10-04 Vijayabhaskar Bolugoddu Preparation of ramipril and stable pharmaceutical compositions
BRPI0710172A2 (pt) * 2006-04-19 2011-08-23 Teva Pharma composição farmacêutica estável de ácido carboxìlico derivado de 2-aza-biciclo[3,3,0]-octana-3
US20100035955A1 (en) * 2006-06-30 2010-02-11 Panagiotis Keramidas Stabilised Composition Comprising ACE Inhibitors
US20080071141A1 (en) * 2006-09-18 2008-03-20 Abhisuek Gattani Method and apparatus for measuring attributes of an anatomical feature during a medical procedure
US8337817B2 (en) * 2006-12-26 2012-12-25 Shin Nippon Biomedical Laboratories, Ltd. Preparation for transnasal application
WO2008132756A1 (en) * 2007-05-01 2008-11-06 Lupin Limited Stable pharmaceutical compositions of ramipril
JP5113476B2 (ja) * 2007-10-09 2013-01-09 沢井製薬株式会社 保存安定性に優れた塩酸テモカプリルの錠剤
JP2012526726A (ja) * 2009-05-15 2012-11-01 株式会社新日本科学 薬物動態が改善された鼻腔内用薬学的組成物
US8827946B2 (en) 2009-07-31 2014-09-09 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
TR200906322A2 (tr) 2009-08-17 2011-07-21 Bi̇lgi̇ç Mahmut Çözünürlük ve stabilite özellikleri geliştirilmiş granüller.
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
TN2010000566A1 (en) * 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
CN102512656B (zh) * 2011-12-27 2013-11-27 天津市嵩锐医药科技有限公司 盐酸喹那普利药物组合物
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320029A (en) 1967-05-16 Method of preparing magnesia
IL58849A (en) 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4344949A (en) 1980-10-03 1982-08-17 Warner-Lambert Company Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
US4425355A (en) 1981-02-17 1984-01-10 Warner-Lambert Company Substituted acyl derivatives of chair form of octahydro-1H-indole-2-carboxylic acids
US4793998A (en) 1986-10-20 1988-12-27 Warner-Lambert Company Stabilized drug compositions
US4830853A (en) 1986-10-20 1989-05-16 Warner-Lambert Company Drug compositions stabilized against oxidation
US4743450A (en) * 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
US4830583A (en) * 1988-03-02 1989-05-16 Sri International Fluid motor-pumping apparatus and system
US5622985A (en) * 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
HU222489B1 (hu) * 1990-07-25 2003-07-28 Novartis Ag. Stabilizált gyógyszerkészítmények és eljárás az előállításukra
IT1251153B (it) * 1991-08-06 1995-05-04 Vectorpharma Int Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica
JP3414539B2 (ja) * 1994-05-11 2003-06-09 有限会社ドット 経鼻吸収用組成物
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
WO1999062560A1 (en) * 1998-06-05 1999-12-09 Warner-Lambert Company Stabilization of compositions containing ace inhibitors using magnesium oxide
NZ333206A (en) * 1998-12-08 2000-07-28 Bernard Charles Sherman Solid pharmaceutical compositions comprising a stable magnesium salt of quinapril that acts as a ACE (Angiotensin Converting Enzyme) inhibitor

Also Published As

Publication number Publication date
IS2270B (is) 2007-07-15
TR200003600T2 (tr) 2001-04-20
AR019150A1 (es) 2001-12-26
JP3727848B2 (ja) 2005-12-21
BR9910947A (pt) 2001-03-06
HK1038879B (zh) 2004-10-08
CO5011043A1 (es) 2001-02-28
JP2002516881A (ja) 2002-06-11
GT199900079A (es) 2000-11-25
ES2242398T3 (es) 2005-11-01
CN1304322A (zh) 2001-07-18
EP1083931B1 (en) 2005-05-11
SV1999000072A (es) 2000-05-04
DE69925269D1 (de) 2005-06-16
TW565455B (en) 2003-12-11
WO1999062560A1 (en) 1999-12-09
ATE295184T1 (de) 2005-05-15
US6417196B1 (en) 2002-07-09
HUP0102260A2 (hu) 2002-03-28
NZ508544A (en) 2002-10-25
IS5712A (is) 2000-11-10
CN1144598C (zh) 2004-04-07
PE20000543A1 (es) 2000-08-10
UY25546A1 (es) 1999-09-27
ZA200006537B (en) 2001-11-12
PA8475001A1 (es) 2000-09-29
AU3979399A (en) 1999-12-20
MY119667A (en) 2005-06-30
DE69925269T2 (de) 2006-02-23
HUP0102260A3 (en) 2002-12-28
ID27398A (id) 2001-04-05
US20060106057A1 (en) 2006-05-18
IL139590A0 (en) 2002-02-10
US20020161020A1 (en) 2002-10-31
EP1083931A1 (en) 2001-03-21
HN1999000088A (es) 2000-02-10
CA2330581A1 (en) 1999-12-09
NO20006148D0 (no) 2000-12-04
KR20010052557A (ko) 2001-06-25
HK1038879A1 (en) 2002-04-04
PL344586A1 (en) 2001-11-05
US7015232B2 (en) 2006-03-21
AU755616B2 (en) 2002-12-19

Similar Documents

Publication Publication Date Title
NO20006148D0 (no) Stabilisering av preparater inneholdende ACE inhibitorer ved anvendelse av magnesiumoksyd
NO20006483L (no) Forbindelser av ustabile dipeptidyl peptidase IV-inhibitorer
ID24372A (id) SENYAWA-SENYAWA 4-AMINO-TIAZOL-2-IL SEBAGAI PENGHAMBAT-PENGHAMBAT CDKs
IL129407A0 (en) Inhibitors of serine proteases particularly hepatitis C virus NS3 protease pharmaceutical compositions containing the same and the use thereof
AU2055301A (en) Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease
HU9702036D0 (en) New heterocyclic compounds as inhibitors of leucocita-adhesion and wla-4-antagonists
DK1105122T3 (da) Pharmaceutical compositions containing lipase inhibitors
AU4330899A (en) Peptoid and nonpeptoid containing alpha-keto oxadiazoles as serine protease inhibitors
NO20001195D0 (no) Bruddheling ved anvendelse av PTHrP-analoger
ID24638A (id) Senyawa-senyawa anti aritmia bispidina
NO20012424D0 (no) Stabilisering av makrolider
GB9825946D0 (en) Pharmaceutical compounds for the inhibition of hepatitis C virus NS3 protease
AU6111000A (en) Inhibitors of viral helcase
PL339176A1 (en) Derivatives of pyrrolopyrrolone as inhibitors of neutrophilic elastase
DE69806558D1 (de) Stabilisierung von 3-Isothiazolonlösungen
AU2001259817A1 (en) Methods of and compounds for inhibiting calpains
TW342659U (en) Protection structure for corner of suitcase
DE60000343D1 (de) Stabilisierung von isothiazolonen
EP1085872A4 (en) TRANSCRIPTION FACTOR NF- $ g (k) B INHIBITORS
ID24677A (id) Kombinasi senyawa aktif fungisidal
EP1309552A4 (en) COMPOUNDS AND INHIBITORS OF PHOSPHOLIPASES
NO20005301D0 (no) Pyrrolidiner som inhibitorer av neuraminidaser
HUP0201636A1 (en) Indol derivative as spla2 inhibitor and pharmaceutical composition containing it
IL155360A0 (en) Processes for the isolation or purification of plavastatin and compositions containing plavastatin
AU2002214038A1 (en) Inhibitors of transglutaminases